|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02637 HAIXI PHARMA
Nominal 
180.100 +20.100 (+12.563%) Non-current Assets
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Investment Properties | -- | -- | 0 | 0 | 0 |
| Property, plant, equip. & others | -- | -- | 275,057 | 92,986 | 9,597 |
| Land & other Lease Assets | -- | -- | 34,491 | 36,542 | 7,030 |
| Intangible Assets | -- | -- | 0 | 0 | 0 |
| Interests in Asso. & JCEs | -- | -- | 0 | 0 | 0 |
| Other Non-current Assets | -- | -- | 100,013 | 98,183 | 54,160 |
| -- | -- | 409,561 | 227,711 | 70,787 | |
Current Assets
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Inventories | -- | -- | 35,333 | 24,801 | 28,373 | |
| Trade Receivables | -- | -- | 19,808 | 19,589 | 6,034 | |
| Cash & Bank Balances | -- | -- | 38,282 | 254,324 | 171,477 | |
| Other Current Assets | -- | -- | 252,835 | 35,119 | 144,289 | |
| Assets Held for Sale | -- | -- | 0 | 0 | 0 | |
| -- | -- | 346,258 | 333,833 | 350,173 | ||
Current Liabilities
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |||
| Trade Payables | -- | -- | 15,783 | 2,804 | 3,109 | ||
| S-T Debt & Leases | -- | -- | 24,634 | 11,039 | 49,316 | ||
| Other Current Liabilities | -- | -- | 141,656 | 103,201 | 37,660 | ||
| Liab asso w/ Assets Held for Sale | -- | -- | 0 | 0 | 0 | ||
| -- | -- | 182,073 | 117,044 | 90,085 | |||
| Net Current Assets | -- | -- | 164,185 | 216,789 | 260,088 | ||
| Total Assets Less Current Liabilities | -- | -- | 573,746 | 444,500 | 330,875 | ||
Non-current Liabilities
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||||
| L-T Debt & Leases | -- | -- | 32,248 | 39,051 | 42,861 | |||
| Other Non-current Liabilities | -- | -- | 171 | 202 | 233 | |||
| -- | -- | 32,419 | 39,253 | 43,094 | ||||
Capital and Reserves
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |||||
| Share Capital | -- | -- | 67,207 | 67,207 | 67,207 | ||||
| Reserves | -- | -- | 474,120 | 338,040 | 220,574 | ||||
| Others | -- | -- | 0 | 0 | 0 | ||||
| Shareholders' Funds | -- | -- | 541,327 | 405,247 | 287,781 | ||||
| Non-controlling Interests | -- | -- | 0 | 0 | 0 | ||||
| Others | -- | -- | 0 | 0 | 0 | ||||
| -- | -- | 541,327 | 405,247 | 287,781 | |||||
Commitments and Contingent Liabilities
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Commitments | -- | -- | 27,015 | 140,812 | 2,834 |
| Contingent Liabilities | -- | -- | 0 | 0 | 0 |
| Remarks: | Real time quote last updated: 01/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 177,029 |
| %Change | 30.093% |
| EPS / (LPS) | RMB 2.550 |
| NBV Per Share (¥) | RMB -- |